Quantcast

Industry news that matters to you.  Learn more

Archives for July 2010

Rules-Base Medicine Gets Award to Develop Cancer Biomarker Assays

Rules-Based Medicine today said it has received an award for about $3 million to fund the research and development of more than double the number of cancer-associated biomarker assays in its new OncologyMap product.

New Multiplex Panels from Aushon BioSystems Help Measure Urinary Biomarkers of Kidney Damage during Drug Development

Aushon BioSystems, Inc., a leading provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis, has launched new Human multiplex biomarker panels for the quantification of eight biomarkers related to drug-induced kidney damage, or nephrotoxicity. Recent studies identifying biomarkers for kidney injury during pre-clinical testing for certain drugs helped initiate the development of the new panels. Requiring minimal sample volume, the new multiplex biomarker panels address the need for a more rapid, sensitive and accurate method to identify and quantify renal toxicity biomarkers to assist in determining risk.

Biomarkers in Demand but CROs Cautious, Study

Demand for biomarker analysis is strong, but the pace of technological change is causing an investment headache for CROs according to a new report by Industry Standard Research (ISR). The research, “The State of Biomarkers in Drug Development,” examined the attitudes of 37 top pharmaceutical and biotechnology companies with regard to the use of biomarkers in clinical development.